Dexcom (DXCM) HR chief granted 39,019 RSUs, 17,199 shares withheld for tax
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Dexcom EVP and Chief HR Officer Sadie Stern received a grant of 39,019 restricted stock units (RSUs) of Common Stock on March 8, 2026. These RSUs are scheduled to vest in three equal annual installments from the grant date, with each RSU representing a right to receive one Dexcom share.
On the same date, 17,199 shares were withheld by the company at a price of $68.10 per share to cover tax obligations related to RSU settlement; this is explicitly described as not being a sale by Stern. Following these transactions, Stern directly holds 131,510 shares of Common Stock, including 77,603 unvested RSUs with various grants vesting through March 8, 2029.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Stern Sadie
Role
EVP, Chief HR Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 39,019 | $0.00 | -- |
| Tax Withholding | Common Stock | 17,199 | $68.10 | $1.17M |
Holdings After Transaction:
Common Stock — 148,709 shares (Direct)
Footnotes (1)
- Represents a grant of restricted stock units (RSUs) that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. RSUs represent a contingent right to receive one share of DexCom, Inc. Common Stock. Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of RSUs and does not represent a sale by the Reporting Person. Included in this number are 77,603 unvested RSUs, 39,019 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 19,948 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 11,399 of which were granted on March 8, 2025 and shall vest through March 8, 2027, and 7,237 of which were granted on March 8, 2024 and shall vest through March 8, 2027.
FAQ
What did Dexcom (DXCM) executive Sadie Stern report in this Form 4?
Sadie Stern reported a grant of 39,019 restricted stock units and related tax-withholding share dispositions. These moves reflect routine equity compensation and associated tax handling, leaving her with 131,510 Dexcom Common Stock shares directly held after the reported transactions.
How many Dexcom (DXCM) RSUs were granted to Sadie Stern and how do they vest?
Sadie Stern received 39,019 restricted stock units that vest in three equal annual installments from March 8, 2026. Each RSU represents a contingent right to receive one share of Dexcom Common Stock upon vesting, aligning compensation with long-term company performance.
How many unvested Dexcom (DXCM) RSUs does Sadie Stern have and what are their schedules?
Sadie Stern has 77,603 unvested RSUs, including 39,019 granted March 8, 2026 vesting through March 8, 2029. Additional tranches were granted March 8, 2025 and March 8, 2024, with vesting dates running through March 8, 2028 and March 8, 2027 respectively.